A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Preserved Antigen-Specific Immune Response in Patients with Multiple Sclerosis Responding to IFN beta-Therapy
Tekijät: Mehling M, Fritz S, Hafner P, Eichin D, Yonekawa T, Klimkait T, Lindberg RLP, Kappos L, Hess C
Kustantaja: PUBLIC LIBRARY SCIENCE
Julkaisuvuosi: 2013
Journal: PLoS ONE
Tietokannassa oleva lehden nimi: PLOS ONE
Lehden akronyymi: PLOS ONE
Artikkelin numero: ARTN e78532
Vuosikerta: 8
Numero: 11
Sivujen määrä: 17
ISSN: 1932-6203
DOI: https://doi.org/10.1371/journal.pone.0078532
Tiivistelmä
Background: Interferon-beta (IFN beta) regulates the expression of a complex set of pro-as well as anti-inflammatory genes. In cohorts of MS patients unstratified for therapeutic response to IFN beta, normal vaccine-specific immune responses have been observed. Data capturing antigen-specific immune responses in cohorts of subjects defined by response to IFN beta-therapy are not available.Objective: To assess antigen-specific immune responses in a cohort of MS patients responding clinically and radiologically to IFN beta.Methods: In 26 MS patients, clinical and MRI disease activity were assessed before and under treatment with IFN beta. Humoral and cellular immune response to influenza vaccine was prospectively characterized in these individuals, and 33 healthy controls by influenza-specific Enzyme-Linked Immunosorbent Assay (ELISA) and Enzyme Linked Immuno Spot Technique (ELISPOT).Results: Related to pre-treatment disease activity, IFN beta reduced clinical and radiological MS disease-activity. Following influenza vaccination, frequencies of influenza-specific T cells and concentrations of anti-influenza A and B IgM and IgG increased comparably in MS-patients and in healthy controls.Conclusions: By showing in a cohort of MS-patients responding to IFN beta vaccine-specific immune responses comparable to controls, this study indicates that antigen-specific immune responses can be preserved under successful IFN beta-therapy.
Background: Interferon-beta (IFN beta) regulates the expression of a complex set of pro-as well as anti-inflammatory genes. In cohorts of MS patients unstratified for therapeutic response to IFN beta, normal vaccine-specific immune responses have been observed. Data capturing antigen-specific immune responses in cohorts of subjects defined by response to IFN beta-therapy are not available.Objective: To assess antigen-specific immune responses in a cohort of MS patients responding clinically and radiologically to IFN beta.Methods: In 26 MS patients, clinical and MRI disease activity were assessed before and under treatment with IFN beta. Humoral and cellular immune response to influenza vaccine was prospectively characterized in these individuals, and 33 healthy controls by influenza-specific Enzyme-Linked Immunosorbent Assay (ELISA) and Enzyme Linked Immuno Spot Technique (ELISPOT).Results: Related to pre-treatment disease activity, IFN beta reduced clinical and radiological MS disease-activity. Following influenza vaccination, frequencies of influenza-specific T cells and concentrations of anti-influenza A and B IgM and IgG increased comparably in MS-patients and in healthy controls.Conclusions: By showing in a cohort of MS-patients responding to IFN beta vaccine-specific immune responses comparable to controls, this study indicates that antigen-specific immune responses can be preserved under successful IFN beta-therapy.
Turun yliopiston Tutkimustietojärjestelmän portaali